Saturday, 15 December 2018
Latest news
Main » FDA Expands Usage Of HPV Vaccine To Adults Aged 27 To 45

FDA Expands Usage Of HPV Vaccine To Adults Aged 27 To 45

12 October 2018

Gardasil can protect individuals from nine types of HPV that are responsible for developing cervical, vaginal, vulvar, and anal cancers. Studies have shown the vaccine to be almost 90 percent effective in preventing cancers and precancerous lesions.

Certain strains of the virus can cause cancer and other diseases.

Dr. Ross says that if you have HPV, you're not alone.

Three vaccines are available to prevent infection by some HPV types: Gardasil (used in Armenia), Cervarix, and Gardasil 9.

More news: Migrants to call regional Australia home under Government's new population plan

The Food and Drug Administration has approved an HPV vaccine for men and women from the ages of 27 to 45, potentially protecting another generation of people from the cancer-causing virus. The latest version of the vaccine protects against 9 strains of HPV, which is 4 more than the original, the article reported. And for those who are older than 26 are recommended to have 3 doses.

The Centers for Disease Control recommends boys and girls receive the HPV (human papillomavirus) vaccine starting at age 11 or 12 years old, with a second dose 6-12 months later.

Most HPV infections cause no symptoms and resolve spontaneously.

In a survey returned by more than 1,900 medical students and 1,000 residents, recognition of the link between HPV and cervical cancer was almost universal, but only about half of the respondents were aware of the relationship between HPV and head and neck cancer, Benjamin Laitman, MD, PhD, of the Icahn School of Medicine at Mount Sinai in New York City, reported here at the 2018 meeting of the American Academy of Otolaryngology-Head and Neck Surgery Foundation.

More news: International Monetary Fund to launch financial assistance talks with Pakistan

"Although most studies have shown a general link between HPV and HIV co-infection, our findings illustrate the strong relationship between individual HPV types and HIV infection", said lead author Brandon Brown, Associate Professor at the University of California, Riverside. This new recommendation is sure to generate discussion, but there's still confusion about what the vaccine does and why it's recommended. But new data show the vaccine can also benefit older adults because they are not often exposed to all nine strains covered by the vaccine. The FDA approving Gardasil 9 for women 27 to 45 years of age is based on this study and longer-term follow-up from it. "This further illustrates the potential utility of HPV vaccine for men who have sex with men and trans women, not only for HPV prevention but also possibly for HIV prevention", Brown added.

In a large study of approximately 3200 women aged 27 through 45 who were given Gardasil and followed for an average of 3.5 years, the vaccine was 88 percent effective in the prevention of a combined endpoint of persistent infection, genital warts, vulvar and vaginal precancerous lesions, cervical precancerous lesions, and cervical cancer related to HPV types covered by the vaccine.

But what about the whole idea of giving the vaccine to young people before they become sexually active?

More news: The FSF Wants Microsoft To Do More To Help Fight Software Patents

FDA Expands Usage Of HPV Vaccine To Adults Aged 27 To 45